Similar to this finding, the present study observed not only no association between tamoxifen therapy and incident urinary incontinence but also a negative and statistically significant association for the prescription of aromatase inhibitors and urinary incontinence risk. The gene discussed is CYP19A1; the disease is Urinary incontinence.